Ginkgo Bioworks Holdings (DNA) EBIT Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported EBIT Margin of 366.51% for Q1 2026, down 15471.0% on a YoY basis from N/an in Q1 2025, and down 73.0% quarter-over-quarter from 211.86% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) EBIT Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported EBIT Margin for 7 years, with the latest figure at 366.51% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 15471.0% year-over-year to 366.51%; the trailing twelve-month figure through Mar 2026 stood at 210.66% (down 711.0% YoY), and the FY2025 full-year result was 185.29%, up 6125.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 366.51%, down from 211.86% in the prior quarter.
- The five-year high for EBIT Margin was 61.99% in Q3 2024, with the low at 986.38% in Q3 2022.
- Historically, EBIT Margin has averaged 347.85% across 5 years, with a median of 267.34% in 2023.
- The largest YoY upside for EBIT Margin was 89966 bps in 2022 against a maximum downside of 95202 bps in 2022.
- Ginkgo Bioworks Holdings' EBIT Margin stood at 234.89% in 2022, then slumped by 118 bps to 512.49% in 2023, then soared by 54 bps to 236.29% in 2024, then advanced by 10 bps to 211.86% in 2025, then plunged by 73 bps to 366.51% in 2026.
- The last three EBIT Margin figures came in at 366.51% (Q1 2026), 211.86% (Q4 2025), and 231.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | -366.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -366.51% |
| Dec 31, 2025 | -211.86% |
| Sep 30, 2025 | -231.78% |
| Jun 30, 2025 | -132.13% |
| Mar 31, 2025 | -211.80% |
| Dec 31, 2024 | -236.29% |
| Sep 30, 2024 | -61.99% |
| Jun 30, 2024 | -396.66% |
| Mar 31, 2024 | -469.12% |
| Dec 31, 2023 | -512.49% |
| Sep 30, 2023 | -516.68% |
| Jun 30, 2023 | -228.57% |
| Mar 31, 2023 | -267.34% |
| Dec 31, 2022 | -234.89% |
| Sep 30, 2022 | -986.38% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |
| Jun 30, 2021 | -137.38% |